0001493152-23-039834.txt : 20231108 0001493152-23-039834.hdr.sgml : 20231108 20231108081031 ACCESSION NUMBER: 0001493152-23-039834 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231108 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Microbot Medical Inc. CENTRAL INDEX KEY: 0000883975 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 943078125 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19871 FILM NUMBER: 231386051 BUSINESS ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 BUSINESS PHONE: 908-938-5561 MAIL ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 FORMER COMPANY: FORMER CONFORMED NAME: STEMCELLS INC DATE OF NAME CHANGE: 20000524 FORMER COMPANY: FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
false 0000883975 0000883975 2023-11-08 2023-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 8, 2023

 

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-19871   94-3078125

(State or other jurisdiction

of incorporation)

   (Commission
File Number)		  

(IRS Employer

Identification No.)

 

288 Grove Street, Suite 388

Braintree, MA 02184

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 875-3605

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   MBOT   NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01 Other Events

 

On November 8, 2023, Microbot Medical Inc. (the “Company”) issued a press release announcing that it had been granted a registered trademark from the US Patent and Trademark Office. The trademark “One & Done®” was given to the feature of the LIBERTY Robotic Surgical System which is being developed to integrate guidewires, microcatheters and other instruments required for complete endovascular procedures using the device.

 

The press release, which is filed as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit   Description
99.1   Press release, dated November 8, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  MICROBOT MEDICAL INC.
   
  By: /s/ Harel Gadot
  Name: Harel Gadot
  Title: Chief Executive Officer, President and Chairman

 

Date: November 8, 2023

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark Office

 

BRAINTREE, Mass., November 8, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the US Patent and Trademark Office. The trademark “One & Done®” was given to the feature of the LIBERTY Robotic Surgical System which is being developed to integrate guidewires, microcatheters and other instruments required for complete endovascular procedures using the device.

 

With this trademark, the Company continues to expand its proprietary assets, including numerous approved and pending patents all over the world, and differentiate its product’s capabilities.

 

About Microbot Medical

 

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.

 

The LIBERTY Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.

 

Further information about Microbot Medical is available at http://www.microbotmedical.com.

 

Safe Harbor

 

Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of LIBERTY, the outcome of its studies to evaluate LIBERTY, whether the Company’s core business focus program and cost reduction plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while it stabilizes its financial condition and seeks additional working capital, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, such as employees of Microbot and its vendors and business partners being called to active military duty, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

 

Investor Contact:

 

Michal Efraty

+972-(0)52-3044404

IR@microbotmedical.com

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 mbot-20231108.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 mbot-20231108_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 mbot-20231108_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2023
Entity File Number 000-19871
Entity Registrant Name MICROBOT MEDICAL INC.
Entity Central Index Key 0000883975
Entity Tax Identification Number 94-3078125
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 288 Grove Street
Entity Address, Address Line Two Suite 388
Entity Address, City or Town Braintree
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02184
City Area Code (781)
Local Phone Number 875-3605
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol MBOT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000883975 2023-11-08 2023-11-08 iso4217:USD shares iso4217:USD shares false 0000883975 8-K 2023-11-08 MICROBOT MEDICAL INC. DE 000-19871 94-3078125 288 Grove Street Suite 388 Braintree MA 02184 (781) 875-3605 false false false false Common Stock, $0.01 par value MBOT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://microbotmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mbot-20231108.xsd mbot-20231108_lab.xml mbot-20231108_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "MBOT", "nsuri": "http://microbotmedical.com/20231108", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mbot-20231108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mbot-20231108_lab.xml" ] }, "presentationLink": { "local": [ "mbot-20231108_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://microbotmedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-039834-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-039834-xbrl.zip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